Navigation Links
Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
Date:1/28/2009

ubt.

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing clinical diagnostic laboratory tests and drugs to diagnose, treat and prevent cardiovascular disease in people with diabetes. The Company has developed a protein-based clinical laboratory test to identify patients with Hp2-2 diabetes. Tests which identify patients with Hp2-2 diabetes may be useful in identifying diabetic patients at high risk for cardiovascular complications. These patients may benefit from a particular formulation of vitamin E. The Company is also developing a kit to measure CML (carboxy-methyllysine), another potential cardiovascular risk marker.

For more information, please visit the Company's Web site at www.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events described in this press release, the Company's ability to obtain sufficient financing to allow it to continue operations, future clinical development of Synvista Therapeutics' diagnostic tests and product candidates, and other risks identified in Synvista Therapeutics' filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption "Risk Factors" in Synvista Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2007. These filings are available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Synvista Therapeutics undertakes no obligati
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
2. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
3. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
4. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
5. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
6. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
7. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
8. Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
9. Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
10. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... HOUSTON , Dec. 22, 2014 Cyberonics, Inc. ... devices for the treatment and management of epilepsy, today announced ... Morgan Healthcare Conference on Wednesday, January 14, 2015, in ... , Cyberonics, President and Chief Executive Officer, will speak at ... presentation can be accessed by clicking on the Investor Relations ...
(Date:12/22/2014)... Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies addressing ... issued the following open letter to shareholders from ... Med. Sc. Dear RXi Shareholders, ... of inaccurate statements posted on certain social media ...
(Date:12/22/2014)... ALTO, Calif. , Dec, 22, 2014 /PRNewswire/ ... a Phase 2a study of lonafarnib in patients ... study was conducted at the National Institutes of ... Maryland .  The double-blinded, randomized, placebo-controlled, dose ... mg twice daily and 200 mg twice daily ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... the University of Illinois at Chicago are taking part ... 2,000 autism patients and their families over the next ... Collection, is the first coordinated effort to create a ... child. , "This collection of DNA will allow researchers ...
... since last year mean seniors should shop wisely, experts ... the enrollment period for Medicare,s Part D prescription drug ... are advising seniors to choose a plan carefully because ... plan. , "As we enter the fourth year of ...
... published by The Feinstein Institute for Medical ... and disease pathogenesis at the molecular level ... use that knowledge in the design of ... prognosis, and prevention. Featured in the ...
... software free of charge to customers purchasing its market leading ... ... Fort Collins, CO (PRWEB) November 14, 2008 -- Privacy ... Email Integrity Program for customers purchasing Privacy Networks, market leading ...
... diagnostic measures, British researchers report , , THURSDAY, Nov. 13 ... standard test for measuring the activity of the heart ... problems for people who are examined because of chest ... stable chest pain, suspected angina, the resting EKG was ...
... Nov. 13 The U.S. government,through the U.S. ... five planned shipments of U.S. emergency assistance to ... In coordination with the,UN Children,s Fund (UNICEF), approximately ... 5,400 water containers, 500,rolls of plastic sheeting, and ...
Cached Medicine News:Health News:UIC joins international research effort to study autism 2Health News:Enrollment for Medicare Drug Plans Begins Again 2Health News:Enrollment for Medicare Drug Plans Begins Again 3Health News:Researchers Tackle CLL, Diabetes and Trauma-Hemorrhage, 2Health News:Message Archiving Leader Privacy Networks Announces Free Anti-Spam Software to Businesses and Organizations 2Health News:Message Archiving Leader Privacy Networks Announces Free Anti-Spam Software to Businesses and Organizations 3Health News:EKG Not Strong Predictor of Heart Risk 2Health News:EKG Not Strong Predictor of Heart Risk 3Health News:First U.S. Flight with Humanitarian Goods Arrives in Democratic Republic of Congo 2
REFRESH TEARS® lubricating eye drops does more than just smoothe and relieve dry, irritated eyes. REFRESH TEARS® creates a shield of protection against further irritation with its unique, lon...
... REFRESH ENDURA™ is the ... to benefit all 3 layers ... coating of moisture that lubricates ... your eyes). This helps seal ...
ALPHAGAN® (brimonidine tartrate ophthalmic solution) 0.2% is indicated for lowering IOP in patients with open-angle galucoma or ocular hypertension....
... solution is a prescription eye drop ... to use after your cataract surgery. ... may cause them to become inflamed. ... inflammation include redness and swelling. If ...
Medicine Products: